Antiangiogenic drugs as a novel anticancer therapeutic strategy which are the more promising agents? What are the clinical developments and indications?

Critical Reviews in Oncology/Hematology

Volumn 26, Issue 3, 1997, Pages 147-162

  Gasparini, Giampietro ^a  

^a BIANCHI MELACRINO MORELLI HOSPITAL   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOGENESIS INHIBITOR;

ANGIOGENESIS; ANTINEOPLASTIC ACTIVITY; CANCER; CANCER ADJUVANT THERAPY; HUMAN; REVIEW; TUMOR BLOOD FLOW;

EID: 0031406307     PISSN: 10408428     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1040-8428(97)10001-4     Document Type: Article

References (121)

1. Pinedo HM, Giaccone G. Chemotherapy. Lancet 1997;349 Suppl II:7-9.
2. Yokes EE. Combined modality therapy of solid tumours. Lancet 1997;349 Suppl II:4-6.
3. Bailar JC III, Gornik HL. Cancer undefeated. N Engl J Med 1997;336:1569-1574.
4. Gasparini G, Harris AL. Does improved control of tumour growth require an anti-cancer therapy targeting both neoplastic and intratumoral endothelial cells?. Eur J Cancer 1994;30A:201-6.
5. Jan RY. Vascular and interstitial barriers to delivery of therapeutic agents in tumors. Cancer Met Rev 1990;9:2253-66.
6. Folkman J. Tumor angiogenesis: therapeutic implications. N Engl J Med 1971;285:1182-6.
7. Harris AL. Antiangiogenesis for cancer therapy. Lancet 1997;349 Suppl II:13-15.
8. Dvorak HF. Tumors: Wounds that not heal. Similarities between tumor stroma generation and wound healing. N Engl J Med 1986;315:1650-9.
9. Fidler IJ. Modulation of the organ microenvironment for treatment of cancer metastasis. J Natl Cancer Inst 1995;87:1588-92.
10. Kerbel RS. Inhibition of tumor angiogenesis as a strategy to circumvent acquaired resistance to anti-cancer therapeutic agents. BioEssays 1991;13:31-6.
11. Rak J, Filmus J, Kerbel RS. Reciprocal paracrine interactions between tumour cells and endothelial cells: the 'angiogenesis progression' hypothesis. Eur J Cancer 1996;32A:2438-50.
12. Folkman J. What is the evidence that tumors are angiogenesis dependent?. J Natl Cancer Inst 1989;82:4-6.
13. Bouck N, Stellmach V, Hsu SC. How tumors become angiogenic. In: Vande Woude GF, Klein G, editors. Advances in cancer research, Vol. 69. New York: Academic Press, 1996:135-174.
14. Hanahan D, Folkman J. Patterns of emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 1996;86:353-64.
15. O'Reilly MS, Holmgren L, Chen C, et al. Angiostatin induces and sustains dormancy of human primary tumors. Nature Med 1996;2:689-92.
16. Holmgren L, O'Reilly MS, Folkman J. Dormancy of micrometastases: Balanced proliferation and apoptosis in the presence of angiogenesis suppression. Nature Medicine 1995;1:149-53.
17. Fox SB, Turner GDH, Gatter KC. The increased expression of adhesion molecules ICAM-3, E- and P-selectins on breast cancer endothelium. J Pathol 1995;177:369-76.
18. Folkman J, Shing Y. Angiogenesis (Minireview). J Biol Chem 1992;267:10931-4.
19. Baillie CT, Winslet MC, Bradley NJ. Tumour vasculature - a potential therapeutic target. Br J Cancer 1995;72:257-67.
20. 3 integrins. Science 1995;270:1500-2.
21. Weinstat-Saslow DL, Zabrenetzky VS, VanHoutte K, et al. Transfection of thrombospondin 1 complementary DNA into a human breast carcinoma cell line reduces primary tumor growth, metastatic potential, and angiogenesis. Cancer Res. 1994;54:6504-11.
22. Voest EE, Kenyon BM, O'Reilly MS, et al. Inhibition of angiogenesis in vivo by interleukin-12. J Natl Cancer Inst 1995;87:581-6.
23. Maione TE, Gray GS, Petro J, et al. Inhibition of angiogenesis by recombinant human platelet factor-4 and related peptides. Science 1990;247:77-9.
24. Clapp C, Martial JA, Guzman RC, et al. The 16-kilodalton N-terminal fragment of human prolactin is a potent inhibitor of angiogenesis. Endocrinology 1993;133:1292-8.
25. Van Meir EG, Polverini PJ, Chazin VR, et al. Release of an inhibitor of angiogenesis upon induction of wild type p53 expression in glioblastoma cells. Nature Genet 1994;8:171-6.
26. Ingber D, Fujita T, Kishimoto S, et al. Synthetic analogues of fumagallin that inhibit angiogenesis and suppress tumour growth. Nature 1990;348:555-7.
27. Vukanovich J, Passaniti A, Hirata T, et al. Antiangiogenic effects of the quinoline-3-carboxamide linomide. Cancer Res 1993;53:1833-7.
28. D'Amato RJ, Loughnan MS, Flynn E, et al. Thalidomide is an inhibitor of angiogenesis. Proc Natl Acad Sci 1994;91:4082-8.
29. Singh RK, Gutman M, Bucana CD, et al. Interferons α and β down-regulate the expression of basic fibroblast growth factor in human carcinomas. Proc Natl Acad Sci USA 1995;92:4562-6.
30. Alessandro R, Spooster J, Liotta LA et al. Inhibition of angiogenesis by CAI, a novel inhibitor of signal transduction. Proc Am Ass Cancer Res (abstr 1102) 1994;35:184.
31. Hori A, Sasada R, Matsutani E, et al. Suppression of solid tumor growth by immunoneutralizing monoclonal antibody against human basic fibroblast growth factor. Cancer Res 1991;51:6180-4.
32. Kim KJ, Li B, Winer J, et al. Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo. Nature 1993;362:841-4.
33. Olson KA, Fett JW, French TC, et al. Angiogen in antagonists prevent tumor growth in vivo. Proc Natl Acad Sci USA 1995;92:442-6.
34. Stein CA, LaRocca RV, Thomas R, et al. Suramin: An anticancer drug with a unique mechanism of action. J Clin Oncol 1989;7:449-509.
35. Stein CA. Suramin: A novel antineoplastic agent with multiple potential mechanisms of action. Cancer Res 1993;53:2239-48.
36. Ranson MR, Jayson GC, Scarffe HJ. Suramin - an important lead compound for a new class of anticancer drugs. Forum 1995;5:238-49.
37. Pluda JM, Shay LE, Foli A, et al. Administration of pentosan polysulfate to patients with human immuno deficiency virus-associated Kaposi's sarcoma. J Natl Cancer Inst 1993;85:1585-92.
38. Watson SA, Morris TM, Robinson G, et al. Inhibition of organ invasion by the matrix metalloproteinase inhibitor batimastat (BB-94) in two human colon carcinoma metastasis models. Cancer Res 1995;55:3629-33.
39. Talbot DC, Brown PD. Experimental and clinical studies on the use of matrix metalloproteinase inhibitors for the treatment of cancer. Eur J Cancer 1996;32A:2523-33.
40. Paulus HE. Minocycline treatment of rheumatoid arthritis. Ann Intern Med 1995;122:147-8.
41. Kwaan, H.C., Verrusio, E., Yoshida, E., et al. Modulation of tumor growth and angiogenesis by PAI-1. Proc Am Assoc Cancer Res (abstr 405) 1994;35:68.
42. Folkman J, Ingber DE. Angiostatic steroids. Method of discovery and mechanism of action. Ann Surg 1987;206:374-83.
43. Folkman J, Weisz PB, Joullié MH, et al. Control of angiogenesis with synthetic heparin substitutes. Science 1989;243:1490-3.
44. Brooks PC, Stromblad S, Klemke R, et al. Anti-integrin αvβ3 blocks human breast cancer growth and angiogenesis in human skin. J Clin Invest 1995;96:1815-22.
45. Teicher BA. A systems approach to cancer therapy. (Antiangiogenics + standard cytotoxics - mechanism(s) of interaction). Cancer Met Rev 1996;15:247-72.
46. Cordon-Cardo C, O'Brien JP, Boccia J, et al. Expression of the multidrug resistance gene product (P-Glycoprotein) in human normal and tumor tissues. J Histochem Cytochem 1990;38:1277-87.
47. Terrier P, Townsend AJ, Coindre JM, et al. An immunohistochemical study of Pi class glutathione S-transferase expression in normal human tissues. Am J Pathol 1990;137:845-53.
48. Klauber N, Parangi S, Flynn E, et al. Inhibition of angiogenesis and breast cancer in mice by the microtubule inhibitors 2-methoxyestradiol and taxol. Cancer Res 1997;57:81-6.
49. Belotti D, Vergani V, Drudis T, et al. The microtubule-affecting drug paclitaxel has antiangiogenic activity. Clin Cancer Res 1996;2:1843-9.
50. Folkman J. Angiogenesis in cancer, vascular, rheumatoid and other disease. Nature Med 1995;1:27-31.
51. Teicher BA, Sotomayor EA, Huang ZD. Antiangiogenic agents potentiate cytotoxic cancer therapies against primary and metastatic disease. Cancer Res 1992;52:6702-4.
52. Auerbach W, Auerbach R. Angiogenesis inhibition: A review. Pharm Ther 1994;63:265-311.
53. Gasparini G. Angiogenesis research up to 1996. A commentary on the state of art and suggestions for future studies. Eur J Cancer 1996;32A:2379-85.
54. Tanaka T, Manome Y, Wen P, et al. Viral vector-mediated transduction of a modified platelet factor 4 cDNA inhibits angiogenesis and tumor growth. Nature Med 1997;3:437-42.
55. Volpert OV, Ward WF, Lingen MW, et al. Captopril inhibits angiogenesis and slows the growth of experimental tumors in rats. J Clin Invest 1996;98:671-9.
56. Panet R, Markus M, Atlan H. Bumetanide and furosemide inhibited vascular endothelial cell proliferation. J Cell Physiol 1994;158:121-7.
57. Lenz W, Thalidomide and congenital abnormalities. Lancet 1962;i:45.
58. Ching L-M, Xu Z-F, Gummer BH, et al. Effect of thalidomide on tumour necrosis factor production and anti-tumour activity induced by 5,6-dimethylxanthenone-4-acetic acid. Br J Cancer 1995;72:339-43.
59. Jacobson JM, Greenspan JS, Spritzler J, et al. Thalidomide for the treatment of oral aphthous ulcers in patients with human immunodeficiency virus infection. N Engl J Med 1997;336:1487-93.
60. Phillips PH, Pluda JM, Cheson BD. Clinical trials using thalidomide. Oncology 1996;10:1498-501.
61. Pfeffer MA, Braunwald E, Moye LA, et al. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 1992;327:669-77.
62. Warren JB, Loi RJ. Captopril increases skin microvascular blood flow secondary to bradykinin, nitric oxide, and prostaglandins. FASEB J P;1995:411-418.
63. Vogt B, Frey FJ. Inhibition of angiogenesis in Kaposi's sarcoma by captopril. Lancet 1997;349:1148.
64. Dvorak HF, Gresser I. Microvascular injury in pathogenesis of interferon-induced necrosis of subcutaneous tumors in mice. J Natl Cancer Inst 1989;81:497-502.
65. a therapy for life-threatening hemangiomas of infancy. New Engl J Med 1992;326:1456-63.
66. Gagliardi A, Collins DC. Inhibition of angiogenesis by antiestrogens. Cancer Res 1993;53:533-5.
67. Noguchi S, Motomura K, Inaji H, et al. Down-regulation of transforming growth factor-α by tamoxifen in human breast cancer. Cancer 1993;72:131-6.
68. Macaulay VM, Fox SB, Zhang H, et al. Breast cancer angiogenesis and tamoxifen resistance. End-Rel Cancer 1995;2:97-103.
69. Gasparini G, Fox SB, Verderio P, et al. Determination of angiogenesis adds information to estrogen-receptor status in predicting the efficacy of adjuvant tamoxifen in node-positive breast cancer patients. Clin Cancer Res 1996;2:1191-8.
70. D'Amato RJ, Lin CM, Flynn E, et al. 2-methoxyestradiol, an endogenous mammalian metabolite, inhibits tubulin polymerization by interacting at the colchicine site. Proc Natl Acad Sci 1994;91:3964-8.
71. Fotsis TH, Zhang Y, Pepper MS, et al. The endogenous oestrogen metabolite 2-methoxyoestradiol inhibits angiogenesis and suppresses tumour growth. Nature 1994;368:237-9.
72. Yamamoto T, Terada N, Nishizawa Y, et al. Angiostatic activities of medroxyprogesterone acetate and its analogues. Int J Cancer 1994;56:393-9.
73. Liaudet-Coopman EDE, Berchem GJ, Wellstein A. In vitro inhibition of angiogenesis and induction of apoptosis by retinoic acid in squamous cell carcinoma. Clin Cancer Res 1997;3:179-84.
74. Kusaka M, Sudo K, Matsutani E, et al. Cytostatic inhibition of endothelial cell growth by the angiogenesis inhibitor TNP-470 (AGM-1470). Br J Cancer 1994;69:212-6.
75. Maier JAM, Delia D, Thorpe PE, et al. In vitro inhibition of endothelial cell growth by the antiangiogenic drug AGM-1470 (TNP-470) and the anti-endoglin antibody TEC-11. Anti-Cancer Drugs 1997;8:238-44.
76. Kusaka M, Sudo K, Fujita T, et al. Potent anti-angiogenic action of AGM-1470: comparison to the fumagallin parent. Biochem Biophys Res Commun 1991;174:1070-6.
77. Abe J, Zhou W, Takuwa N, et al. A fumagallin-derivative angiogenesis inhibitor, AGM-1470, inhibits activiation of cyclin-dependent kinases and phosphorylation of retinoblastoma gene product, but not protein tyrosyl phosphorylation or protooncogene expression in vascular endothelial cells. Cancer Res 1994;54:3407-12.
78. Antoine N, Bours V, Heinen E, et al. Stimulation of human B-lymphocyte proliferation by AGM-1470, a potent inhibitor of angiogenesis. J Natl Cancer Inst 1995;87:136-9.
79. Brem H, Ingber D, Blood CH, et al. Suppression of tumor metastasis by angiogenesis inhibition. Am Coll Surg, Surg Forum 1991;42:439-41.
80. Yamaoka M, Yamamoto T, Masaki T, et al. Inhibition of tumor growth and metastasis of rodent tumors by the angiogenesis inhibitor O-(chlorocetyl-carbomoyl)fumagillol (TNP-470; AGM-1470). Cancer Res 1993;53:4262-7.
81. Yanase T, Tamura M, Fujita K, et al. Inhibitory effect of angiogenesis inhibitor TNP-470 on tumor growth and metastasis of human cell lines in vitro and in vivo. Cancer Res 1993;53:2566-70.
82. Tanaka T, Konno H, Matsuda I, et al. Prevention of hepatic metastasis of human colon cancer by angiogenesis inhibitor TNP-470. Cancer Res 1995;55:836-9.
83. Mori S, Ueda T, Karatsu S, et al. Suppression of pulmonary metaastasis by angiogenesis inhibitor TNP-470 in murine osteosarcoma. Int J Cancer 1995;61:148-52.
84. Konno H, Tanaka T, Matsuda I, et al. Comparison of the inhibitory effect of the angiogenesis inhibitor, TNP-470, and mitomycin C on the growth and liver metastasis of human colon cancer. Int J Cancer 1995;61:268-71.
85. Teicher BA, Holden SA, Ara G, et al. Potentiation of cytotoxic cancer therapies by TNP-470 alone and with other anti-angiogenic agents. Int J Cancer 1994;57:920-5.
86. Teicher BA, Holden SA, Dupuis NP, et al. Potentiation of cytotoxic therapies by TNP-470 and minocycline in mice bearing EMT-6 mammary carcinoma. Breast Cancer Res Treat 1995;36:227-36.
87. Parangi S, O'Reilly M, Christofori G, et al. Anatiangiogenic therapy of transgenic mice impairs de novo tumor growth. Proc Natl Acad Sci USA 1996;93:2002-7.
88. McLeskey SW, Zhang L, Trock BJ, et al. Effects of AGM-1470 and pentosan polysulphate on tumorigenicity and metastasis of FGF-transfected MCF-7 cells. Br J Cancer 1996;73:1053-62.
89. Toi M, Yamamoto Y, Imazawa T, et al. Antitumor effect of the angiogenesis inhibitor AGM-1470 and its combination effect with tamoxifen in DMBA incuded mammary tumors in rats. Int J Oncol 1993;3:525-8.
90. Kakeji Y, Teicher BA. Preclinical studies of the combination of angiogenic inhibitors with cytotoxic agents. Invest New Drugs 1997;15:39-48.
91. Teicher BA, Dupuis N, Kusumoto T, Robinson MF, Liu F, Menon K, Coleman CN. Antiangiogenic agents can increase tumor oxygenation and response to radiation therapy. Radiation Oncol Invest 1995;2:269-76.
92. Klauber N, Rohan RM, Flynn E, et al. Critical components of the female reproductive pathway are suppressed by the angiogenesis inhibitor AGM-1470. Nature Med 1997;3:443-6.
93. Castronovo V, Belotti D. TNP-470 (AGM-1470): mechanisms of action and early clinical development. Eur J Cancer 1996;32A:2520-7.
94. Ingber DE, Folkman J. Inhibition of angiogenesis through modulation of collagen metabolism. Lab Invest 1988;59:44-50.
95. Teicher BA, Sotomayor EA, Huang ZD, et al. β-Cyclodextrin tetradecasulfate/tetrahydrocortisol + minocycline as modulators of cancer therapies in vitro and in vivo against primary and metastatic Lewis lung carcinoma. Cancer Chemother Pharmacol 1993;33:229-38.
96. Braddock PS, Hu D-E, Fan T-PD, et al. A structure-activity analysis of antagonism of the growth factor and angiogenic activity of basic fibroblast growth factor by suramin and related polyanions. Br J Cancer 1994;69:890-8.
97. Eckhardt SG, Burris HA, Eckhardt JR, et al. A phase I clinical trial and pharmacokinetic study of the angiogenesis inhibitor, tecogalan sodium. Ann Oncol 1996;7:491-6.
98. Gasparini G, Presta M. Clinical studies with angiogenesis inhibitors: Biological rational and challenges for their evaluation. Ann Oncol 1996;7:441-4.
99. Kalland T. Effects of the immunomodulator LS 2616 on growth and metastasis of the murine B16-F10 melanoma. Cancer Res 1986;46:3018-22.
100. Ichikawa T, Lamb JC, Christensson PI, et al. The antitumor effects of the quinoline-3-carboxamide linomide on dunning R-3327 rat prostatic cancers. Cancer Res 1992;52:3022-8.
101. Vukanovic J, Isaac JT. Linomide inhibits angiogenesis, growth, metastasis, and marcrophage infiltration within rat prostatic cancers. Cancer Res 1995;55:1499-504.
102. Vukanovic J, Isaacs JT. Human prostatic cancer cells are sensitive to programmed (apoptotic) death induced by the antiangiogenic agent linomide. Cancer Res 1995;55:3517-20.
103. Ziche M, Gasparini G, Choudhuri R, et al. Antiangiogenic effect of linomide on breast cancer VEGF transfectants. Oncol Rep 1997;4:253-6.
104. Bengtsson M, Simonsson B, Carlsson K, et al. Stimulation of NK cell, T cell, and monocyte functions by the novel immunomodulator linomide after autologous bone marrow transplanation. Transplantation 1992;53:882-8.
105. de Wit R, Pawinsky A, van Oosterom AT, et al. EORTC Phase II study of daily oral linomide in metastatic renal cell carcinoma patients with good prognostic factors. Eur J Cancer 1997;33:493-5.
106. Pawinski A, van Oosterom AT, de Wit R, et al. An EORTC phase II study of the efficacy and safety of linomide in the treatment of advanced renal cell carcinoma. Eur J Cancer 1997;33:496-9.
107. Ferrara N. Vascular endothelial growth factor. Eur J Cancer 1996;32A:2413-22.
108. Borgstrom P, Torres Fihlo IP, Hartley-Asp B. Anti-angiogenic effects of the quinoline-3-carboxamide, linomide, on tumor induced angiogenesis studied with a new in vivo technique. Proc Am Ass Cancer Res (abstr 403) 1994;35:68.
109. 121. Cancer Res 1995;55:5296-301.
110. Relf M, LeJeune S, Scott PAE, et al. Expression of the angiogenic factors vascular endothelial cell growth factor, acidic and basic fibroblast growth factor, tumor growth factor β-1, platelet-derived endothelial growth factor, placenta growth factor, and pleiotrophin in human primary breast cancer and its relation to angiogenesis. Cancer Res 1997;57:963-9.
111. 3 for angiogenesis. Science 1994;264:569-71.
112. Burrows FJ, Thorpe PE. Eradication of large solid tumors in mice with an immunotoxin directed against tumor vasculature. Proc Natl Acad Sci USA 1993;90:8996-9000.
113. Huang X, Molema G, King S, et al. Tumor infarction in mice by antibody-directed targeting of tissue factor to tumor vasculature. Science 1997;275:547-50.
114. Harris AL, Clinical trials of anti-vascular agent CM 101. Angiogenesis 1997;1 (in press).
115. Fox SB, Harris AL. Markers of tumor angiogenesis; clinical applications in prognosis and anti-angiogenesis therapy. Invest New Drugs 1997;15:15-29.
116. Gasparini G, Toi M, Gion M, et al. Prognostic significance of vascular endothelial growth factor protein in node-negative breast carcinoma. J Natl Cancer Inst 1997;89:139-47.
117. Nguyen M, Watanabe H, Budson AE, et al. Elevated levels of an angiogenic peptide, basic fibroblast growth factor, in the urine of patients with a wide spectrum of cancers. J Natl Cancer Inst 1994;86:356-61.
118. Taniguchi T, Toi M, Inada K, et al. Serum concentrations of hepatocyte growth factor in breast cancer patients. Clin Cancer Res 1997;1:1031-4.
119. Nguyen M, Watanabe H, Budson AE, et al. Elevated levels of an angiogenic peptide, basic fibroblast growth factor, in the urine of bladder cancer patients. J Natl Cancer Inst 1994;85:241-2.
120. Gasparini G, Harris AL. Clinical importance of the determination of tumor angiogenesis in breast carcinoma: Much more than a new prognostic tool. J Clin Oncol 1995;13:765-82.
121. Eckhardt SG, Pluda JM. Development of angiogenesis inhibitors for cancer therapy. Invest New Drugs 1997;15:1-3.